3.48
+0.01(+0.29%)
Currency In USD
| Previous Close | 3.47 |
| Open | 3.48 |
| Day High | 3.48 |
| Day Low | 3.48 |
| 52-Week High | 7.92 |
| 52-Week Low | 3.32 |
| Volume | 20,307 |
| Average Volume | 30,434 |
| Market Cap | 37.11M |
| PE | -1.86 |
| EPS | -1.87 |
| Moving Average 50 Days | 4.58 |
| Moving Average 200 Days | 5.17 |
| Change | 0.01 |
If you invested $1000 in Serina Therapeutics, Inc. (SER) since IPO date, it would be worth $35.95 as of December 05, 2025 at a share price of $3.48. Whereas If you bought $1000 worth of Serina Therapeutics, Inc. (SER) shares 5 years ago, it would be worth $56.65 as of December 05, 2025 at a share price of $3.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Serina Therapeutics Provides Regulatory Update on SER-252 Program
GlobeNewswire Inc.
Nov 03, 2025 11:05 AM GMT
- FDA requests additional information on a formulation component - HUNTSVILLE, AL, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Pl
Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors
GlobeNewswire Inc.
Oct 08, 2025 3:00 PM GMT
HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the launch o
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease
GlobeNewswire Inc.
Oct 06, 2025 8:15 PM GMT
$5 million tranche received under up to $20 million financing agreementIND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Se